Calliditas Therapeutics IPO Presentation Deck
Disclaimers
Important information
Calliditas Therapeutics AB (the "Company") has filed a registration statement (including a preliminary prospectus) with the Securities and Exchange Commission ("SEC") for the offering to which this presentation relates. Before you
invest, you should read the preliminary prospectus in that registration statement and the other documents the Company has filled with the SEC for more complete information about the Company and the offering. You may get these
documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, the Company or any underwriter or dealer participating in this offering will arrange to send you the prospectus if you request it from Citigroup
Global Markets Inc., c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 1-800-831-9146, or email [email protected]; Jefferies LLC, Attention: Equity Syndicate Prospectus Department,
520 Madison Avenue, 2nd Floor, New York, New York 10022, via telephone: 877-821-7388 or via email: [email protected]; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery
Street, Suite 3700, San Francisco, CA 94104, or by telephone at (415) 364-2720 or by email at [email protected]. This presentation shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor
shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
The presentation does not purport to give legal, tax or financial advice, and must not be relied upon for any such purpose. Neither the information contained in this presentation, nor any further information made available by the
Company or any of its affiliates or employees, directors, representatives, officers, agents, or advisors, in connection with this presentation will form the basis of or be construed as a contract or any other legal obligation.
This presentation may contain certain forward-looking statements and opinions. Forward-looking statements are statements that do not relate to historical facts and events and such statements and opinions pertaining to the future
that, by example, contain wording such as "believes", "estimates", "anticipates", "expects", "assumes", "forecasts", "intends", "could", "will", "should", "would", "according to estimates", "is of the opinion", "may", "plans",
"potential", "predicts", "projects", "to the knowledge of or similar expressions, which are intended to identify a statement as forward-looking. This applies, in particular, to statements and opinions in this presentation concerning our
future business expectations, the therapeutic potential and clinical development of our product candidates, including with respect to trial design, enrollment, milestones and data readout, the regulatory pathways for our product
candidates, including our plans for the submission of marketing applications to the regulatory authorities in the relevant jurisdictions for approval of our product candidates, our plans for pre-commercial and, if approved, commercial
activities that we may undertake to market our product candidates, our collaborations for the development and commercialization of our product candidates, the market opportunity for the disease indications that our product
candidates are intended to address, our plans for the in-licensing or acquisition of additional product candidates for our pipeline, our future financial returns, plans and expectations with respect to our business and management,
future growth and profitability and general economic and regulatory environment and other matters affecting our company. Forward-looking statements are based on current estimates and assumptions made according to the best
of our knowledge. Such forward-looking statements are subject to risks, uncertainties, and other factors that could cause the actual results, including with respect to our business, cash flow, financial condition and results of
operations, to differ materially from the results, or fail to meet expectations expressly or implicitly assumed or described in those statements or to turn out to be less favorable than the results expressly or implicitly assumed or
described in those statements. Accordingly, readers should not place undue reliance on the forward-looking statements herein. We can give no assurance regarding the future accuracy of the opinions set forth herein or as to the
actual occurrence of any predicted developments. In light of the risks, uncertainties and assumptions associated with forward-looking statements, it is possible that the future events mentioned in this presentation may not occur.
Actual results, performance or events may differ materially from those in such statements due to, without limitation, risks generally associated with pharmaceutical development, including delays or challenges that may arise in the
clinical development of our product candidates, interactions with regulatory authorities, the impacts of the COVID-19 pandemic, challenges in the commercialization of our product candidates, if approved, the risk that we may not
maintain our existing collaboration or enter into new ones, or that we will not realize the intended benefits from such collaborations, any inability to expand our pipeline of product candidates, any inability to maintain barriers to
entry such as intellectual property protection or regulatory exclusivity, changes in general economic conditions, in particular economic conditions in the markets on which we operate, changes affecting interest rate levels, changes
affecting currency exchange rates, changes in competition levels and changes in laws and regulations. The information, opinions and forward-looking statements contained in this announcement speak only as at its date, and are
subject to change without notice.
Certain information, including certain forward-looking estimates and forecasts, contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the
Company's own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the
adequacy, fairness, accuracy or completeness of any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be
no guarantee as to the accuracy or reliability of such assumptions. Finally, while we believe our own internal research is reliable, such research has not been verified by any independent source.View entire presentation